NEW YORK – April 3, 2017 – IRX Therapeutics, Inc. (IRX) today announced that Mark Leuchtenberger, the Company’s President and Chief Executive Officer, will present a corporate overview at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference on Friday, April 7, 2017, at 3:00 p.m. Eastern time. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.
IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells, to recognize and destroy tumors. For more information about the Company and its clinical programs, please visit www.IRXTherapeutics.com.
MacDougall Biomedical Communications
Kari Watson, 781-235-3060